A Belgian company that produces biopharmaceuticals is joining forces with British Industry Bicycle Therapeutics to develop new drugs and treatments for the opthalmic industry.
The firm ThromboGenics is now in a new relationship that will actively seek to utilize the Bicycle 'peptides' in the research and further development of pharmaceuticals for treatment of diabetic macular edema.
The condition occurs when protein deposits and excess fluid amass on or under the eye's macula which causes it to abnormally swell. This will distort vision of the patient as that particular area contains cones that give us clear central vision and colour that is directly in the direction of the eyes gaze.
ThromboGenics, which specializes in eye treatment, will pay Bicycle an undisclosed upfront fee and payments related to development and regulatory milestones.